

ISSN 2572-0376

Vol.0 No.0

Primary Intracranial Fibrosarcoma Presenting with Hemorrhage

Young-Cho Koh

Konkuk University Medical Center, Seoul, Korea

Abstract

 $\mathbf{P}_{\text{rimary intracranial fibrosarcomas (PIFs)}}$ are extremely rare and the origin of these tumors is still con-troversial. The rarity of primary intracranial fibrosarcomas makes it difficult to diagnose them correctly and establish a standard treatment. The pathologic diagnosis is made by distinguishing findings from light microscopic and immunohistochemistry analysis. PIFs have been known to be very aggressive neoplasms. The extraaxial location of the tumor could provide an opportunity to perform a total resec- tion even if it does not mean a cure. We present a case of PIFs mimicking a falx meningioma in a 17year- old man.

Key Words Fibrosarcoma; Primary CNS origin; Differential diagnosis

Introduction

Primary intracranial fibrosarcomas (PIFs) are very rare and aggressive tumors. Only 41 cases have been reported in the literature to date [1,2]. Intracranial sarcomas are found in patients of all ages, although a greater number of young patients were reported in earlier studies [3]. It is thought that primary meningeal sarcoma originates from fibroblastic elements within the brain parenchyma or its meningeal coverings. Tumor bleeding is an uncommon event of this tumor [4]. The common location of PIFs is supratentorial and superficial, adherent to the dura mater.

In this report, we report a rare case of PIF mimicking a falx meningioma presenting with intratumoral hemorrhage in an adolescent.

Case Report

A 17-year-old man presented to our hospital with an epi- sode of convulsions. The patient complained of a three-month history of headache before visiting a hospital. A papilledema with decreased visual acuity was detected on neurological examination. Computed tomography revealed a large extra-axi- al mass with hemorrhage occupying both frontal areas (Fig. 1A). Magnetic resonance images showed a large mass with strong enhancement and T2 iso-signal intensity in both frontal lobes abutting against the falx cerebri (Fig. 1B-D).

Both distal anterior cerebral arteries (ACAs) were encapsulated by the tumor. Trans-femoral cerebral angiography revealed that both ACAs were the main tumor-feeding arteries and both ACAs had multiple aneurysms, which may be aberrantly developed from increased blood flow (Fig. 1E, F).

The patient underwent surgical tumor resection after a presumed diagnosis of falx meningioma or hemangiopericytoma. Profuse bleeding from the hypervascular tumor made it difficult to resect the tumor at one stage. The tumor was well-demarcated and quite soft in a superficial portion but it was very hard in the deeper area (Fig. 2). The second and third operations were performed at 10 days and 17 days after the first surgery, respectively. The aneurysm located at the A2-3 junction was ruptured in the middle of the surgery but clipping the neck of the aneurysm was safely performed without compromising the ACA. Maximal safe resection was performed through three serial operations and only a small part of the tumor, which was tightly adhered to the ACA, remained (Fig. 3A-C). After the surgery, neurological examinations revealed a left sidehemiparesis.

Histologically, the tumor based on the dura (Fig. 4A) was composed of a high cellular proliferation arranged in sheets occasionally showing a herringbone and fascicular pattern al-Primary Intracranial Fibrosarcoma.






Fig. 1. Large mass with hemorrhage originating from the falx cerebi (A: Non-enhanced CT, B: T2-weighted MR), ACA was encapsulated by the tumor (white arrow). Well-enhancing tumor with hemorrhage and suspicious brain parenchyma invasion on gadolinium enhancement (C: Axi- al view, D: Coronal view). Large hypervascular mass in both frontal areas fed by pial branches of both ACAs. Multiple aneurysm, ecstatic changes and luminal irregularities in the A2-3 junction (E: Angiography, F: Angiography 3D). CT: computed tomography, MR: magnetic reso- nance, ACA: anterior cerebral artery, 3D: three dimension.




Fig. 2. Well-demarcated hypervascular tumor.

ternating (Fig. 4B) with an abundant extracellular collagenous matrix formation (Fig. 4C). No whorling of tumor cells or psammoma bodies were present. And malignant small round cell features were seen focally (Fig. 4D). High mitotic activity was noted up to 25 per 10 high power fields. Differential diagnosis included malignant spindle cell tumors including malignant hemangiopericytoma, malignant solitary fibrous tumor, monomorphic synovial sarcoma, Ewing's sarcoma and fibrosarcoma. Immunostains including CD34, CD68, S-100, smooth-muscle actin, desmin, myoglobin, CD99, epithelial membrane antigen, glial fibrillary acidic protein, CD56, mixed cytokeratin and INI-1 were performed. The tumor cells showed strong vimentin immunoreactivity and no loss of INI-1 immunoreactivity, and were negative for the other immunofluorescence stainings including epithelial membrane antigen (EMA), CD99 and CD34. Fusion gene transcripts including EWS-EWS-FLI1 t (11;22) specific for Ewing's sarcoma and SYT/SSX t (X;18) specific for synovial sarcoma were not observed by reverse transcription-polymerase reaction. These histologic, immunohistochemical and molecular findings made a confirmatory diagnosis of the fibrosarcoma and excluded the other possibilities of sarcomas in the tumor of the patient. Intracranial metastasis of systemic sarcoma was ruled

Vol.0 No.0






Fig. 3. Images of MRI and PET-CT. A: Residual tumor in the bifrontal region (1st stage post-operation). B: Further resection of residual tumor (2nd stage post-operation). C: Small residual tumor in the anterior pericallosal region (3rd stage post-operation). D: No significant abnormal hypermetabolic lesion suggesting malignancy except brain. PET-CT: positron emission tomography-CT.




Fig. 4. Histologic features of tumor. A: Tumor based on the dura (H&E, \times 40). B: Malignant spindle cell proliferation with herringbone and fas- cicular pattern (H&E, \times 200). C: Tumor with abundant extracellular collagenous matrix production (H&E, \times 200). D: Focal presence of malignant small round cell features (H&E, \times 200).

out by positron emission tomography computed tomography (PET-CT) (Fig. 3D). He received gamma knife radiosurgery for the residual mass at 14 days after the last surgery. At that time, the tumor size was 1.3 cc, and he received a dose of 18 Gy, which was prescribed to the 55% isodose line.

Discussion

The rarity of PIFs makes it difficult to diagnose correctly. Primary intracranial sarcomas account for 0.5-2.7% of intracranial neoplasms [5,6]. However, in up-to-date papers, the incidence of fibrosarcoma was reported in only one of 25,000 cases. The reason for the decrement in the incidence is thought to be due to advances in diagnostic techniques, result-ing in previously misdiagnosed fibrosarcomas being diag-nosed as other tumors such as malignant fibrous histio- cytomas [3]. PIFs occur in all ages but are more prevalent in younger ages and are known to have a poor prognosis. Spon-taneous hemorrhage from PIFs has been reported in a few cases but the incidence is not clearly documented to date [4]. PIFs may be induced secondarily by radiation and immuno- suppressive therapy. Because PIFs are thought to arise from the mesenchymal cells in duramater, leptomeninges, vascular adventitia, the stalk of the choroid plexus or tela choroidea, the origin of PIFs is still under debate [7]. A differential diagnosis is needed with malignant meningioma, hemangiompericyto- ma, gliosarcoma, Ewing's sarcoma, and so on. Pathologically, fibrosacroma of the brain is a rare primary malignancy and shares the same histologic features at any oth- er body site. It is mandatory to exclude other malignant spin- dle cell tumors to make a final diagnosis of fibrosarcoma. Cli- nical impression of a meningioma in this patient was easily ruled out due to a lack of whorling of tumor cells or psammo- ma bodies and EMA immunonegativity.



Vol.0 No.0

No staghorn-branch- ing vascular pattern, immunonegativity of CD34 and CD99, and no fusion gene transcripts were able to exclude a possibil- ity of major differential diagnoses including malignant heman- giopericytoma, malignant solitary fibrous tumor, monomor- phic synovial sarcoma, or Ewing's sarcoma. A classical herr- ing-bone arrangement of the tumor cells and abundant ex- tracellular collagenous matrix primarily suggested a fibro- sarcoma rather than other spindle cell malignancies [1,8]. All these findings confirmed the diagnosis of a primary fibrosar- coma of the brain based on the leptomeninges. There is no standard treatment for primary intracranial fi- brosarcoma due to its rarity and poor prognosis. In our case, three serial operations were performed for maximal safe re- section. The remaining tumor was treated by radiosurgery and adjuvant chemotherapy. In the absence of established treatment, complete or maximal safe resection could provide the opportunity for longer survival to the patient.

References

- 1. Chopra R, Bhardwaj M, Premsagar IC. Fibrosarcoma of the meninges. Rare Tumors 2010;2:e3.
- 2. Torres G, Petit F, Vilchez V, et al. Primary cerebral fibrosarcoma in a child. Clin Neuropathol 2007;26:284-7.
- 3. Bisogno G, Roganovic J, Carli M, et al. Primary intracranial fibrosarco- ma. Childs Nerv Syst 2002;18:648-51.
- 4. McDonald P, Guha A, Provias J. Primary intracranial fibrosarcoma with intratumoral hemorrhage: neuropathological diagnosis with review of the literature. J Neurooncol 1997;35:133-9.
- 5. Vatsal DK, Sharma S, Renjen PN, Kaul S, Jha AN. Primary fibrosarco- ma of brain. Neurol India 2000;48:396-8.
- 6. Paulus W, Slowik F, Jellinger K. Primary intracranial sarcomas: histo- pathological features of 19 cases. Histopathology 1991;18:395-402.
- Donnet A, Figarella-Branger D, Grisoli F. Primary meningeal fibrosar- coma: a particular neuroradiological presentation. J Neurooncol 1999; 42:79-83.
- 8. Cai N, Kahn LB. A report of primary brain fibrosarcoma with literature review. J Neurooncol 2004;68:161-7.

6th International Conference on Neuro-Oncology and Brain Tumor, Webinar- June 22-23, 2020.